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Edited by Veli-Pekka LehtoAbstract Circulating HGF is signiﬁcantly increased in a num-
ber of thrombus-associated disorders. Since platelets play a piv-
otal role in thrombogenesis, the ability of HGF to interact with
human platelets was investigated. This paper shows for the ﬁrst
time that human platelets express HGF receptor, the tyrosine ki-
nase encoded by c-MET gene. At physiological concentrations
HGF was found to inhibit both glycoprotein aIIbb3 activation
and thrombin-dependent platelet aggregation in a dose- and
time-dependent manner. These results suggest that circulating
HGF may counteract thrombogenesis by negatively modulating
platelet functions.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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factor1. Introduction
The hepatocyte growth factor (HGF) is a pleiotropic cyto-
kine, which elicits multiple biological responses, namely motility,
proliferation, morphogenesis and survival in a cell type-depen-
dent fashion. These phenomena are essential in physiological
processes, such as organ formation during embryogenesis
and tissue homeostasis in adults; however, when inappropri-
ately activated, they may contribute to tumour development
and metastasis [1,2]. HGF shares several structural features
with proteins of the blood coagulation cascade: the presence
of characteristic ‘‘kringle’’ domains, a zymogen activation site
and a C-terminal serine protease-like domain. HGF is secreted
by cell of mesenchymal origin as an inactive single chain pre-
cursor (pro-HGF) and in this form is found in serum and in
the extracellular matrix of several tissues, where it is stored
bound to proteoglycans [3]. Upon tissue injury, upregulation
of speciﬁc convertases induces a local burst of active HGF that
limits cell damage and promotes tissue regeneration [4].
HGF receptor (HGF-R) is the MET protooncogene en-
coded transmembrane tyrosine kinase [5,6] and is predomi-Abbreviations: HGF, hepatocyte growth factor; PDGF, platelet-deri-
ved growth factor; VEGF, vascular endothelial growth factor; SCF,
stem cell factor; Thr, thrombin; PBS, phosphate buﬀered saline
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activity is dependent on the transphosphorylation of its kinase
domain and of a multifunctional docking site [9], which causes
the concomitant activation of multiple signal transduction
pathways that account for the complex biological responses
elicited by HGF [1,2].
Much evidence suggests that the HGF/Met receptor couple
is involved in the homeostasis of the cardiovascular system:
(i) they play an important role in the early cardiac develop-
ment, when they are transiently expressed [10], (ii) endogenous
and exogenous HGF have a cardioprotective activity in exper-
imental myocardial infarction [11], (iii) HGF is a potent angio-
genic factor [12]. Moreover, HGF levels in the plasma of
patients with acute myocardial infarction [13] or arterial
thrombosis [14] are signiﬁcantly and precociously increased
and a correlation between the increase in circulating HGF
and hypertension [15] and atherosclerosis [16] has been re-
ported. The key role played by platelets in the formation of
atheromatose plaques and thrombi is established [14,16].
Although HGF was originally puriﬁed from human platelets
[17] and growing evidence suggest the involvement of HGF
in thrombotic events, the expression of Met on the platelet sur-
face and the eﬀects of HGF on platelet function have not yet
been investigated. All the above has prompted us to investigate
the possible role of HGF/Met in platelet function.
Here we show that platelets express the Met receptor at their
surface, and that HGF can inhibit thrombin-induced platelet
aggregation, downregulating integrin aIIbb3 activation.2. Materials and methods
2.1. Materials
Recombinant human hepathocyte growth factor (HGF) was from
PeproTech EC (London, UK). The DO-24 monoclonal antibody is
speciﬁc for the extracellular domain of the Met receptor [18]. Poly-
clonal FITC-conjugated rabbit anti-mouse IgG antibodies were from
DAKO (Glostrup, DK). FITC-conjugated PAC-1 antibody was from
Becton Dickinson (San Jose, CA). Monoclonal antibody against Myc
(9E10) and thrombin (Thr) from human plasma were purchased from
Sigma–Aldrich (St. Louis, MO). All other reagents were of analytical
grade.2.2. Platelet preparation and aggregation studies
Blood was withdrawn from healthy volunteers who had not taken
any drugs for at least two weeks before venipuncture. ACD (130 mM
citric acid, 152 mM sodium citrate, and 112 mM glucose) was used as
anticoagulant. Platelets, obtained by gel-ﬁltration on Sepharose CL-
2B as previously described [19], were used for all experiments. Platelet
samples were preconditioned at 37 C and incubated with HGFation of European Biochemical Societies.
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or not with 0.02 U/ml thrombin, under continuous stirring. Platelet
aggregation was monitored for 5 min in a Crono-log aggregometer as
described [19].
2.3. Measurement of Met expression on platelets surface by
ﬂow-cytometry
Aliquots of platelet suspension (109 platelets/ml) were ﬁxed with
0.5% paraformaldehyde, washed three times with phosphate buﬀered
saline (PBS) and incubated for 30 min under constant stirring with
DO-24 or 9E10 (3 lg/ml). After extensive washing, samples were incu-
bated with FITC-conjugated rabbit anti-mouse IgG secondary anti-
bodies (1:50) for further 30 min in the dark. Platelets were diluted
1:20 with PBS and analyzed on a Becton-Dickinson FACScalibur,
acquiring data of 10000 particles per sample.
2.4. Measurement of PAC-1 binding by ﬂow-cytometry
PAC-1 binding to platelets was measured as described by Moro et al.
[19]. Platelets added with 100 pg/ml HGF, 0.02 U/ml thrombin,
0.02 U/ml thrombin 30 s after 100 pg/ml HGF, or buﬀer were treated
with FITC-labelled PAC-1 antibody (2.5 lg/ml) for 10 min at 37 C
and then blocked with 0.5% paraformaldehyde. Flow-cytometry anal-
ysis was carried out as described [19].
2.5. Statistical analysis
Values are reported as means ± S.E.M. The signiﬁcance of diﬀer-
ences was determined with the paired t-test. P < 0.05 was considered
signiﬁcant.Fig. 1. Detection of Met receptor at the platelet surface by ﬂow-
cytometry. (A) Patterns of ﬂuorescence intensity registered in a typical
experiment. (B) Histograms derived from three independent experi-
ments.3. Results
3.1. Met is expressed in human platelets
The expression of Met receptor at the cell surface was inves-
tigated on ﬁxed platelets incubated with the DO-24 antibody
speciﬁc for the Met extracellular domain [18], followed by
FITC-conjugated anti-mouse-IgG secondary antibodies.
Anti-Myc antibody was used as negative control. The ﬂuores-
cence intensity in DO-24 treated cells was 11.3-folds higher
than that measured in control samples (Fig. 1A). The diﬀer-
ence between the mean values of ﬂuorescence intensity mea-
sured in DO-24 and anti-Myc-treated cells (46.3 ± 10.9 and
5.3 ± 0.2, respectively) was statistically signiﬁcant (P < 0.01,
n = 3) (Fig. 1B). It is thus concluded that Met protein is ex-
posed at the platelet surface.
3.2. HGF inhibits thrombin-dependent platelet aggregation and
integrin aIIbb3 activation
To evaluate the functionality and the role of Met receptor in
human platelets, we next investigated the eﬀect of its ligand
HGF on platelet aggregation. Physiological doses of HGF
(1010 g/ml) did not elicit any detectable aggregation in plate-
lets (Fig. 2). Therefore, we considered the possibility that HGF
could modulate platelet aggregation induced by a physiologi-
cal agonist such as thrombin. Indeed, HGF strongly inhibited
aggregation, when added to platelet suspension 30 s before
thrombin (Fig. 2).
HGF inhibited thrombin-dependent aggregation in a dose-
dependent manner, with maximal inhibition (% of inhibition:
80.0 ± 28.8) starting from concentrations of 1010 g/ml
(Fig. 3A). Lower concentrations of HGF (1011–1012 g/ml)
were still inhibitory (% of inhibition: 18.0 ± 5.1 and
6.1 ± 3.3, respectively). These results suggest that HGF aﬀects
thrombin-dependent platelet aggregation acting through a
high aﬃnity membrane receptor.We then performed time-course experiments, in which HGF
(1010 g/ml) was added to platelet samples for diﬀerent periods
of time (10–30–180 s) before thrombin stimulation. The eﬀect
of HGF on thrombin-induced platelet aggregation was rapid
and transient, with the peak of inhibition (80%) at 30 s
(Fig. 3B). Pretreatment with HGF for 10 s caused a slight de-
crease in platelet aggregation (% of inhibition: 14.9 ± 3.1%),
while no inhibition was detected upon HGF preincubation
for 3 min.
Platelet aggregation is dependent on agonist-induced activa-
tion of aIIbb3 integrin, undergoing a conformational change,
which is instrumental for the subsequent ﬁbrinogen binding
[20]. To evaluate a possible involvement of HGF in the aIIbb3
activation pathway, we investigated the activation status of
aIIbb3 integrin by ﬂow-cytometry using the ﬁbrinogen mimetic
FITC-PAC-1 monoclonal antibody. Results from 7 indepen-
dent experiments are reported (Fig. 4). Consistent with its
inability to promote platelet aggregation, HGF alone did not
induce the activation of integrin aIIbb3. Platelets preincubated
for 30 s with 1010 g/ml HGF before stimulation with throm-
bin showed a signiﬁcant decrease in the amount of PAC-1
bound to the cells, when compared with that bound to platelets
stimulated with thrombin alone. The mean values of ﬂuores-
cence intensity detected in thrombin-stimulated platelets were
6.47 ± 1.67 in the absence and 3.13 ± 0.73 in the presence of
Fig. 2. Inhibition of thrombin-induced platelet aggregation by HGF.
Aggregation traces are from a representative experiment out of the six
performed with platelets obtained from diﬀerent donors.
Fig. 3. Dose-dependence (Panel A) and time-course (Panel B) inhibi-
tion of thrombin-induced platelet aggregation by HGF. Light trans-
mission was monitored as described in Fig. 2. Data are reported as %
inhibition of thrombin-induced aggregation in the absence of HGF
and are means ± S.E.M. of six independent experiments performed
with platelets from diﬀerent donors.
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Fig. 4. Inhibition of thrombin-induced activation of aIIbb3 integrin by
HGF. Binding of the FITC labelled ﬁbrinogen mimetic PAC-1
antibody to platelets. Data are means ± S.E.M. of seven independent
experiments performed with platelets from diﬀerent donors.
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50% reduction of the PAC-1 bound to thrombin-stimulated
platelets (*) (P < 0.05; n = 7).4. Discussion
In this work, we report for the ﬁrst time that human platelets
express the HGF receptor at their surface, and that HGF plays
an active role in negatively regulating platelet function. Indeed,
although HGF by itself did not elicit any functional response
in platelets, it triggered a dramatic inhibition of thrombin-in-
duced platelet aggregation, preventing aIIbb3 integrin confor-
mational activation.
HGF receptor expression was clearly detected at the surface
of resting platelets by cytoﬂuorimetry, although we found a
certain heterogenicity in the expression levels of Met within
platelets. HGF inhibited thrombin-dependent platelet aggrega-
tion in a dose-dependent manner, when added to platelets 30 s
before agonist stimulation. Strong inhibition was observed at
picomolar concentrations (1010–1012 g/ml), which are re-
ported to be the optimal doses also in other cell systems, con-
ﬁrming that the high aﬃnity Met receptor was involved in this
eﬀect [6]. The eﬀect of HGF on agonist-dependent platelet
aggregation was rapid and transient, since platelets incubated
with HGF for times longer than 30 s were not inhibited in their
thrombin-induced aggregation. The ﬁnding that only a moder-
ate decrease (25–30%, as measured by ﬂow cytometry, data not
shown) in the cell surface expression of Met receptor was ob-
served upon HGF incubation suggests that a mechanism other
than downregulation is responsible for the absence of a biolog-
ical response at delayed times. Receptor desensitization may be
a possibility. Apparently Met receptor is particularly prone to
inactivation/desensitization, since once platelets were activated
by thrombin, HGF was unable to modulate their response
(data not shown).
Although HGF-dependent inhibitory pathway in activated
platelets remains to be characterized, our results indicated that
HGF inhibits inside–out signalling of the ﬁbrinogen receptor
aIIbb3 [20]. Indeed the eﬀect of HGF on thrombin-dependent
platelet aggregation was found to be a consequence of the inhi-
bition exerted by HGF on thrombin-induced activation of
integrin aIIbb3. Upon stimulation platelets release from their
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let-derived growth factor (PDGF) [21,22] which are thus read-
ily disposable to amplify or modulate platelet responses with
an autocrine–paracrine mechanism, since these cells can ex-
press the cognate receptors [23,24]. Platelets contains also
HGF [17], but it is still debated whether this cytokine is ac-
tively released upon stimulation.
VEGF, as well as the c-Kit ligand stem cell factor (SCF),
were reported to bind and enhance platelet aggregation, but
only if cells were previously activated by physiological agonists
[24,25]. This ﬁnding strongly suggests that the active ligand-
binding conformation of these receptors is not exposed at
the surface of resting platelets, but their priming is required.
By contrast, resting platelets can bind HGF and PDGF and
in these cases ligand-receptor interaction results in inhibition
of thrombin-induced platelet aggregation [data reported here
and 23]. Platelets are easily activated by mechanical and bio-
chemical stimuli; however, all the above growth factors do
not have any eﬀect by themselves, they can only modulate
either positively or negatively platelet activation triggered by
a physiological agonist. The fact that the enhancing factors
VEGF and SCF can exert their eﬀect only on pre-activated
platelets, while the negatively regulating factors PDGF and
HGF can exert their priming eﬀect on resting cells, is rather
intriguing and suggest that this may be part of a more general
mechanism aimed at controlling platelet activation.
Both HGF and PDGF modulate negatively thrombin-
induced platelet aggregation. In vivo they are signiﬁcantly in-
creased in the thrombus, where they could be involved in
controlling platelet activation and limiting thrombus forma-
tion. At systemic level HGF and PDGF concentrations are
similar [13,26], but, since only HGF is able to inhibit platelet
aggregation at these physiological concentrations, PDGF inhi-
bition requiring about 1000 times higher levels, the negative
feedback on some eventual platelet systemic activation would
depend mostly on HGF, while PDGF could act mainly locally.
HGF is a pleiotropic cytokine, which generally promotes po-
sitive cellular responses, such as motility, proliferation, mor-
phogenesis and protection from apoptosis [1]. Its increased
plasmatic levels upon organ injury can be interpreted as an
adaptive response of the organism to cope with the adverse sta-
tus, trying to preserve or recover homeostasis. Indeed it is in-
creased in diﬀerent cardiovascular pathologies, including
hypertension [15], arterial thrombosis and atherosclerosis
[14,16] and myocardial infarction, where its cardioprotective
role has been clearly demonstrated [11]. The negative regula-
tion of platelet activation reported here would anyway result
in a protective, and thus beneﬁcial action, of HGF against vas-
cular thrombotic events.
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